Search
Now showing items 1-6 of 6
Co‑prevalence of human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) in healthy blood donors from diverse nationalities in Qatar
(
BMC
, 2020 , Article)
Background: Infections by both human oncoviruses, human Papillomaviruses (HPV) and Epstein–Barr virus (EBV) are
very common in the adult human population and are associated with various malignancies. While HPV is ...
Incidence of HPVs, EBV and MMTV-like Virus in Breast Cancer in Qatar.
(
Karger Publishers
, 2022 , Article)
Human papillomaviruses (HPVs), Epstein-Barr virus (EBV), and mouse mammary tumor virus-like virus (MMTV-like virus) can be present and contribute to breast cancer development and progression. However, the role of these ...
Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity.
(
MDPI
, 2019 , Article)
Breast cancer is the most frequent cause of cancer-related deaths among women worldwide. It is classified into four major molecular subtypes. Triple-negative breast cancers (TNBCs), a subgroup of breast cancer, are defined ...
Coinfection of HPVs Is Associated with Advanced Stage in Colorectal Cancer Patients from Qatar
(
Multidisciplinary Digital Publishing Institute (MDPI)
, 2023 , Article)
High-risk human papillomaviruses (HPVs) are considered risk factors in the origin of several human malignancies, such as breast, cervical, head and neck, as well as colorectal cancers. However, there are no data reported ...
Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor.
(
Frontiers Media
, 2022 , Article)
Immune checkpoint blockade (ICB)-based therapy is revolutionizing cancer treatment by fostering successful immune surveillance and effector cell responses against various types of cancers. However, patients with HER2+ ...
Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways.
(
Springer Nature
, 2024 , Article)
Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, including breast ...